VELA Investment Management LLC Cuts Stock Position in Bruker Corporation $BRKR

VELA Investment Management LLC decreased its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 22.9% during the second quarter, HoldingsChannel reports. The institutional investor owned 77,459 shares of the medical research company’s stock after selling 23,067 shares during the period. VELA Investment Management LLC’s holdings in Bruker were worth $4,661,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in BRKR. Allworth Financial LP raised its position in Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after acquiring an additional 257 shares during the period. Federated Hermes Inc. grew its position in shares of Bruker by 6.7% in the fourth quarter. Federated Hermes Inc. now owns 6,027 shares of the medical research company’s stock valued at $284,000 after purchasing an additional 380 shares during the period. Parallel Advisors LLC grew its position in shares of Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 479 shares during the period. State of Michigan Retirement System increased its stake in shares of Bruker by 1.9% during the first quarter. State of Michigan Retirement System now owns 26,693 shares of the medical research company’s stock worth $964,000 after purchasing an additional 500 shares in the last quarter. Finally, CWM LLC increased its stake in shares of Bruker by 49.8% during the fourth quarter. CWM LLC now owns 1,631 shares of the medical research company’s stock worth $77,000 after purchasing an additional 542 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Stock Performance

BRKR opened at $58.50 on Monday. The firm has a market capitalization of $8.91 billion, a price-to-earnings ratio of -83.57, a price-to-earnings-growth ratio of 1.79 and a beta of 1.26. The company’s 50 day simple moving average is $58.76 and its two-hundred day simple moving average is $48.73. Bruker Corporation has a 1-year low of $29.84 and a 1-year high of $65.30. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The business had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. During the same period in the prior year, the business earned $0.32 earnings per share. The business’s revenue was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts expect that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, September 21st. Bruker’s dividend payout ratio is presently -28.57%.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Wolfe Research assumed coverage on shares of Bruker in a research note on Monday, June 1st. They issued a “peer perform” rating on the stock. Barclays increased their target price on Bruker from $53.00 to $60.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. Citigroup lowered their price target on Bruker from $60.00 to $53.00 and set a “hold” rating on the stock in a research note on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a research report on Monday, August 31st. Finally, Leerink Partners increased their price objective on Bruker from $60.00 to $70.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Bruker presently has an average rating of “Hold” and a consensus price target of $56.64.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.